WASHINGTON / RankWire.AI / – A rare inherited genetic alteration substantially elevates an individual’s overall likelihood of developing lung cancer by about 25 times, and by nearly 60 times among those who have never smoked, as detailed in a recent publication in the journal Science. The study was a collaborative effort between researchers at the Dana-Farber Cancer Institute and the 23andMe Research Institute. The team analyzed de-identified genomic data from over 3.3 million individuals, identifying the germline variant, known as EGFR T790M, as one of the most potent inherited risk factors for lung cancer discovered so far.
This mutation is found in the epidermal growth factor receptor gene, which plays a key role in controlling cell growth and division within lung tissue. While somatic mutations in EGFR that are acquired during a person’s lifetime are well-established drivers of non-small cell lung cancer, the inherited germline variant T790M is present from birth in every cell. According to data from the National Cancer Institute, this mutation appears in roughly 1 out of every 15,850 individuals in the United States. Lead author Dr. Jaclyn LoPiccolo highlighted that carrying this variant increases lung cancer risk approximately 62 times in individuals who have never smoked, compared to about 11 times in those with a history of tobacco use.
Genetic mapping revealed that the EGFR T790M mutation is disproportionately common among populations in the Southern Appalachian region, spanning Tennessee and Alabama. Evolutionary geneticists traced the origin of the mutation back to British and Irish settlers who migrated to North America during colonial times. The mutation became more prevalent following a genetic bottleneck approximately 200 years ago. Senior study author Dr. Pasi A. Jänne emphasized that although lung cancer screening primarily focuses on tobacco exposure, recognizing strong genetic risk factors opens new avenues for targeted screening with low-dose computed tomography among non-smokers who carry this mutation.
Dana-Farber Cancer Institute’s Research Analyzes 3.3 Million Genomes
Supported by the National Institutes of Health, preclinical and clinical trials confirmed that the mutation exhibits a robust specific link to lung cancer, showing no significant association with 17 other common cancers examined in the dataset. Oncologists pointed out that, although tobacco remains the primary cause of lung cancer overall, cases among non-smokers are an increasing global health concern. Several pharmaceutical companies, including AstraZeneca, are actively developing targeted tyrosine kinase inhibitors like Tagrisso to treat lung cancers with EGFR mutations once tumors progress.
Co-senior author Dr. Alexander Gusev stated that the study illustrates how a single inherited point mutation can have an exceptionally profound impact on disease susceptibility. Medical professionals advise that individuals with multiple family members affected by lung cancer, unexplained multifocal lung nodules, or ancestral connections to Southern Appalachia should seek genetic counseling. The researchers stressed that possession of the mutation does not inevitably lead to lung cancer, as environmental factors and secondary genetic modifications also influence whether malignant transformation occurs during a person’s lifetime.
EGFR Gene’s Role in Cell Growth Regulation
The research team intends to expand observational efforts through the ongoing INHERIT Study, aiming to assess additional inherited variants of EGFR across diverse racial groups. This longitudinal research will seek to identify environmental triggers and secondary genetic changes that determine why some carriers develop tumors while others remain asymptomatic.
Further detailed information regarding population genetics, risk assessments, and screening guidelines is accessible through peer-reviewed medical repositories and official institutional releases. Future updates and biomarker data will be presented at upcoming international oncology conferences to help shape future screening protocols.